4.7 Article

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

期刊

LANCET ONCOLOGY
卷 12, 期 8, 页码 795-805

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(11)70189-9

关键词

-

类别

资金

  1. Merck Serono
  2. Merck KGaA
  3. Roche

向作者/读者索取更多资源

Background Findings from the phase 3 FLEX study showed that the addition of cetuximab to cisplatin and vinorelbine significantly improved overall survival, compared with cisplatin and vinorelbine alone, in the first-line treatment of EGFR-expressing, advanced non-small-cell lung cancer (NSCLC). We investigated whether candidate biomarkers were predictive for the efficacy of chemotherapy plus cetuximab in this setting. Methods Genomic DNA extracted from formalin-fixed paraffin-embedded (FFPE) tumour tissue of patients enrolled in the FLEX study was screened for KRAS codon 12 and 13 and EGFR kinase domain mutations with PCR-based assays. In FFPE tissue sections, EGFR copy number was assessed by dual-colour fluorescence in-situ hybridisation and PTEN expression by immunohistochemistry. Treatment outcome was investigated according to biomarker status in all available samples from patients in the intention-to-treat population. The primary endpoint in the FLEX study was overall survival. The FLEX study, which is ongoing but not recruiting participants, is registered with ClinicalTrials.gov, number NCT00148798. Findings KRAS mutations were detected in 75 of 395 (19%) tumours and activating EGFR mutations in 64 of 436 (15%). EGFR copy number was scored as increased in 102 of 279 (37%) tumours and PTEN expression as negative in 107 of 303 (35%). Comparisons of treatment outcome between the two groups (chemotherapy plus cetuximab vs chemotherapy alone) according to biomarker status provided no indication that these biomarkers were of predictive value. Activating EGFR mutations were identified as indicators of good prognosis, with patients in both treatment groups whose tumours carried such mutations having improved survival compared with those whose tumours did not (chemotherapy plus cetuximab: median 17 . 5 months [95% CI 11 . 7-23 . 4] vs 8 . 5 months [7 . 1-10 . 8], hazard ratio [HR] 0 . 52 [0 . 32-0 . 84], p=0 . 0063; chemotherapy alone: 23 . 8 months [15 . 2-not reached] vs 10 . 0 months [8 . 7-11 . 0], HR 0 . 35 [0 . 21-0 . 59], p<0 . 0001). Expression of PTEN seemed to be a potential indicator of good prognosis, with patients whose tumours expressed PTEN having improved survival compared with those whose tumours did not, although this finding was not significant (chemotherapy plus cetuximab: median 11 . 4 months [8 . 6-13 . 6] vs 6 . 8 months [5 . 9-12 . 7], HR 0 . 80 [0 . 55-1 . 16], p=0 . 24; chemotherapy alone: 11 . 0 months [9 . 2-12 . 6] vs 9 . 3 months [7 . 6-11 . 9], HR 0 . 77 [0 . 54-1 . 10], p=0 . 16). Interpretation The efficacy of chemotherapy plus cetuximab in the first-line treatment of advanced NSCLC seems to be independent of each of the biomarkers assessed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据